TNFRSF9 and neoplasm: We reasoned that the relative lack of therapeutic impact in the face of clear differences in Treg deletion was due to the ability of the anti-mOX40 mAb (like anti-4-1BB mAb) to evoke anti-tumor effects through multiple mechanisms.